^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
iladatuzumab vedotin (DCDS0780A)
i
Other names: DCDS0780A, RG 7986, RG7986, RO7032005
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Pfizer, Roche
Drug class:
Microtubule inhibitor, CD79b-targeted antibody-drug conjugate
Related drugs:
over2years
Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study. (PubMed, Clin Cancer Res)
DCDS0780A as the TDC format for CD79B was tested at higher doses than its ADC counterpart investigated earlier, leading to deep responses. However, dose intensity was limited by ocular toxicities seen at the higher doses indicating that the TDC format was unable, in the current study, to expand the therapeutic index for the CD79B target. The encouraging anti-tumor activity advocates continuation of investigations into novel ADC technologies.
Clinical • P1 data • Journal
|
CD79B (CD79b Molecule)
|
Rituxan (rituximab) • iladatuzumab vedotin (DCDS0780A)
over4years
A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
P1, N=66, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
Clinical • Trial completion • Combination therapy
|
CD19 (CD19 Molecule)
|
Rituxan (rituximab) • Gazyva (obinutuzumab) • iladatuzumab vedotin (DCDS0780A)
Share via
